Cover Image
Market Research Report

Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019

Published by Global Markets Direct Product code 245982
Published Content info 129 Pages
Delivery time: 1-2 business days
Price
Back to Top
Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019
Published: March 18, 2019 Content info: 129 Pages
Description

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019, provides an overview of the Chemotherapy Induced Neutropenia (Toxicology) pipeline landscape.

Chemotherapy-induced neutropenia is a very common side effect of cancer treatment. Symptoms include severe fatigue, weakness, anxiety, lack of energy, shortness of breath, headaches, pale appearance, rapid heart rate or palpitations, chest pain dizziness and abdominal pain. The predisposing factors include age, co-morbidities and time course of therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chemotherapy Induced Neutropenia (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Neutropenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 5, 8, 6 and 8 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Chemotherapy Induced Neutropenia (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Neutropenia (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chemotherapy Induced Neutropenia (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chemotherapy Induced Neutropenia (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chemotherapy Induced Neutropenia (Toxicology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chemotherapy Induced Neutropenia (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Product Code: GMDHC11109IDB

Table of Contents

  • Introduction
  • Chemotherapy Induced Neutropenia - Overview
  • Chemotherapy Induced Neutropenia - Therapeutics Development
  • Chemotherapy Induced Neutropenia - Therapeutics Assessment
  • Chemotherapy Induced Neutropenia - Companies Involved in Therapeutics Development
  • Chemotherapy Induced Neutropenia - Drug Profiles
  • Chemotherapy Induced Neutropenia - Dormant Projects
  • Chemotherapy Induced Neutropenia - Discontinued Products
  • Chemotherapy Induced Neutropenia - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Number of Products under Development by Universities/Institutes, H1 2019
  • Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019 (Contd..1), H1 2019
  • Products under Development by Companies, H1 2019 (Contd..2), H1 2019
  • Products under Development by Universities/Institutes, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by BeyondSpring Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Biocon Ltd, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Bolder Biotechnology Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Cellerant Therapeutics Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Dr. Reddy's Laboratories Ltd, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Enzychem Lifesciences Corp, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Gene Techno Science Co Ltd, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Generon (Shanghai) Corp Ltd, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by GlycoMimetics Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Lupin Ltd, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Mycenax Biotech Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Nohla Therapeutics Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Pangen Biotech Inc., H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Pfizer Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Profarma, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Prolong Pharmaceuticals LLC, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Richter Gedeon Nyrt, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Sandoz International GmbH, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Tanvex BioPharma Inc, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by USV Pvt Ltd, H1 2019
  • Chemotherapy Induced Neutropenia - Pipeline by Valenta Pharmaceuticals, H1 2019
  • Chemotherapy Induced Neutropenia - Dormant Projects, H1 2019
  • Chemotherapy Induced Neutropenia - Dormant Projects, H1 2019 (Contd..1), H1 2019
  • Chemotherapy Induced Neutropenia - Discontinued Products, H1 2019

List of Figures

  • Number of Products under Development for Chemotherapy Induced Neutropenia, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
Back to Top